Daito Pharmaceutical Balance Sheet

Financials in millions JPY. Fiscal year is June - May.

Millions JPY. Fiscal year is Jun - May.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb '26 Feb 28, 2026	May '25 May 31, 2025	May '24 May 31, 2024	May '23 May 31, 2023	May '22 May 31, 2022	May '21 May 31, 2021
Cash & Equivalents	1,871	2,207	2,727	3,607	4,381	3,372
Cash & Short-Term Investments	1,871	2,207	2,727	3,607	4,381	3,372
Cash Growth	-21.35%	-19.07%	-24.40%	-17.67%	29.92%	9.34%
Accounts Receivable	11,612	20,254	15,441	17,654	16,146	12,791
Other Receivables	5,802	-	1,292	-	-	-
Receivables	17,414	20,254	16,733	17,654	16,146	12,791
Inventory	18,298	18,412	20,890	18,238	16,820	15,751
Other Current Assets	726	835	1,110	1,164	562	515
Total Current Assets	38,309	41,708	41,460	40,663	37,909	32,429
Property, Plant & Equipment	31,620	31,826	31,972	25,837	23,116	21,372
Long-Term Investments	2,406	3,579	3,464	3,169	2,958	3,096
Other Intangible Assets	1,085	531	490	377	386	332
Long-Term Deferred Tax Assets	109	359	320	504	570	508
Other Long-Term Assets	1,434	1	2	2	-	2
Total Assets	74,963	78,004	77,708	70,552	64,939	57,739
Accounts Payable	6,810	8,266	8,699	8,172	7,864	7,730
Accrued Expenses	465	1,086	1,051	1,091	1,170	1,106
Short-Term Debt	-	-	-	69	11	11
Current Portion of Long-Term Debt	2,897	3,099	2,099	1,429	1,189	1,362
Current Portion of Leases	502	358	275	15	-	1
Current Income Taxes Payable	464	3,348	4,681	4,288	3,319	2,564
Other Current Liabilities	4,213	892	1,700	364	516	84
Total Current Liabilities	15,351	17,049	18,505	15,428	14,069	12,858
Long-Term Debt	4,403	6,569	4,669	3,368	2,247	2,018
Long-Term Leases	2,348	1,859	1,676	77	-	-
Pension & Post-Retirement Benefits	182	169	320	497	755	764
Long-Term Deferred Tax Liabilities	66	30	32	31	32	28
Other Long-Term Liabilities	280	261	242	180	165	155
Total Liabilities	22,630	25,937	25,444	19,581	17,268	15,823
Common Stock	7,186	7,186	7,186	7,186	7,031	6,271
Additional Paid-In Capital	7,072	7,072	7,072	7,072	6,917	6,157
Retained Earnings	37,702	37,179	37,087	35,006	32,338	28,331
Treasury Stock	-1,285	-749	-990	-124	-13	-13
Comprehensive Income & Other	1,584	1,315	1,713	1,532	1,031	872
Total Common Equity	52,259	52,003	52,068	50,672	47,304	41,618
Minority Interest	74	64	196	299	367	298
Shareholders' Equity	52,333	52,067	52,264	50,971	47,671	41,916
Total Liabilities & Equity	74,963	78,004	77,708	70,552	64,939	57,739
Total Debt	10,150	11,885	8,719	4,958	3,447	3,392
Net Cash (Debt)	-8,279	-9,678	-5,992	-1,351	934	-20
Net Cash Per Share	-278.41	-318.14	-190.94	-42.68	30.50	-0.67
Filing Date Shares Outstanding	29.16	29.99	30.59	31.61	31.7	30.17
Total Common Shares Outstanding	29.16	29.99	30.59	31.61	31.43	30.17
Working Capital	22,958	24,659	22,955	25,235	23,840	19,571
Book Value Per Share	1791.91	1734.24	1702.33	1603.24	1504.87	1379.46
Tangible Book Value	51,174	51,472	51,578	50,295	46,918	41,286
Tangible Book Value Per Share	1754.71	1716.53	1686.31	1591.31	1492.59	1368.45
Order Backlog	-	5,840	5,417	5,223	7,585	6,664

Updated Feb 28, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.